Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells

Vaccine

Volumn 26, Issue 4, 2008, Pages 509-521

  Bernstein, Michael B ^a   Chakraborty, Mala ^a   Wansley, Elizabeth K ^a   Guo, Zhimin ^b   Franzusoff, Alex ^b   Mostböck, Sven ^a   Sabzevari, Helen ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GlobeImmune Inc   (United States)

Author keywords

CEA; Dendritic cells; Saccharomyces cerevisiae; Yeast

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; UPREGULATION; VACCINATION; YEAST;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS; SACCHAROMYCES CEREVISIAE; VACCINATION;

EID: 37849035624     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.033     Document Type: Article

References (40)

1. Franzusoff A., Duke R.C., King T.H., Lu Y., and Rodell T.C. Yeasts encoding tumour antigens in cancer immunotherapy. Exp Opin Biol Ther 5 April (4) (2005) 565-575
2. Brossart P., Goldrath A.W., Butz E.A., Martin S., and Bevan M.J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158 April (7) (1997) 3270-3276
3. Murphy K.M., Heimberger A.B., and Loh D.Y. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250 December (4988) (1990) 1720-1723
4. Stubbs A.C., and Wilson C.C. Recombinant yeast as a vaccine vector for the induction of cytotoxic T-lymphocyte responses. Curr Opin Mol Ther 4 February (1) (2002) 35-40
5. Ballou C.E. A study of the immunochemistry of three yeast mannans. J Biol Chem 245 March (5) (1970) 1197-1203
6. Franzusoff A., and Schekman R. Functional compartments of the yeast Golgi apparatus are defined by the sec7 mutation. EMBO J 8 September (9) (1989) 2695-2702
7. Lu Y., Bellgrau D., Dwyer-Nield L.D., Malkinson A.M., Duke R.C., Rodell T.C., et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 64 August (15) (2004) 5084-5088
8. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7 May (5) (2001) 625-629
9. Owais M., Masood A.K., Agrewala J.N., Bisht D., and Gupta C.M. Use of liposomes as an immunopotentiating delivery system: in perspective of vaccine development. Scand J Immunol 54 July-August (1-2) (2001) 125-132
10. Gold P., and Freedman S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121 March (1) (1965) 439-462
11. Shuster J., Thomson D.M., Fuks A., and Gold P. Immunologic approaches to diagnosis of malignancy. Prog Exp Tumor Res 25 (1980) 89-139
12. Clarke P., Mann J., Simpson J.F., Rickard-Dickson K., and Primus F.J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 58 April (7) (1998) 1469-1477
13. Greiner J.W., Zeytin H., Anver M.R., and Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62 December (23) (2002) 6944-6951
14. Grosenbach D.W., Barrientos J.C., Schlom J., and Hodge J.W. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 61 June (11) (2001) 4497-4505
15. Hodge J.W., Sabzevari H., Yafal A.G., Gritz L., Lorenz M.G., and Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59 November (22) (1999) 5800-5807
16. Kass E., Panicali D.L., Mazzara G., Schlom J., and Greiner J.W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61 January (1) (2001) 206-214
17. Hodge J.W., Rad A.N., Grosenbach D.W., Sabzevari H., Yafal A.G., Gritz L., et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 92 August (15) (2000) 1228-1239
18. Garnett C.T., Palena C., Chakraborty M., Tsang K.Y., Schlom J., and Hodge J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64 November (21) (2004) 7985-7994
19. Mennuni C., Calvaruso F., Facciabene A., Aurisicchio L., Storto M., Scarselli E., et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 117 November (3) (2005) 444-455
20. Haller A.A., Lauer G.M., King T.H., Kemmler C., Fiolkoski V., Lu Y., et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 25 February (8) (2007) 1452-1463
21. Staeheli P., Pitossi F., and Pavlovic J. Mx proteins: GTPases with antiviral activity. Trends Cell Biol 3 8 (1993) 268-272
22. Bulinski J.C. Cell biology. Actin discrimination. Science 313 July (5784) (2006) 180-181
23. Schmitz J., Reali E., Hodge J.W., Patel A., Davis G., Schlom J., et al. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 62 September (17) (2002) 5058-5064
24. Eades-Perner A.M., van der Putten H., Hirth A., Thompson J., Neumaier M., von Kleist S., et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 54 August (15) (1994) 4169-4176
25. Garnett C.T., Greiner J.W., Tsang K.Y., Kudo-Saito C., Grosenbach D.W., Chakraborty M., et al. TRICOM vector based cancer vaccines. Curr Pharm Des 12 3 (2006) 351-361
26. Schlom J., Sabzevari H., Grosenbach D.W., and Hodge J.W. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines. Artif Cells Blood Substit Immobil Biotechnol 31 2, May (2003) 193-228
27. Everson G., Tong M., Jacobson I., Jensen D., Haller A., Lauer G., et al. Interim results from a randomized, double-blind, placebo-controlled phase Ib study in subjects with chronic HCV after treatment with GI-5005, a yeast-based HCV immunotherapy targeting NS3 and core proteins [abstract] (2006), American Association for the Study of Liver Disease p. LB17
28. Whiting S., Cohn A., Morse M., O'Neil S., Bellgrau D., Duke R., et al. Treatment of Ras mutation-bearing solid tumor using whole recombinant S. cerevisiae yeast expressing mutated Ras: preliminary safety and immunogenicity results from a phase I trial [abstract]. Gastrointestinal cancers symposium (2006) 105
29. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 March (6673) (1998) 245-252
30. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., and Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1 October (6) (1999) 362-368
31. Sheng K.C., Pouniotis D.S., Wright M.D., Tang C.K., Lazoura E., Pietersz G.A., et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118 July (3) (2006) 372-383
32. Huang Q., Liu D., Majewski P., Schulte L.C., Korn J.M., Young R.A., et al. The plasticity of dendritic cell responses to pathogens and their components. Science 294 October (5543) (2001) 870-875
33. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184 August (2) (1996) 747-752
34. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E., et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184 August (2) (1996) 741-746
35. Stephens K.E., Ishizaka A., Larrick J.W., and Raffin T.A. Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. Am Rev Respir Dis 137 June (6) (1988) 1364-1370
36. Strieter R.M., Kunkel S.L., and Bone R.C. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21 October (Suppl. 10) (1993) S447-S463
37. Barron M.A., Blyveis N., Pan S.C., and Wilson C.C. Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development. J Clin Immunol 26 May (3) (2006) 251-264
38. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23 4, Feb 1 (2005) 720-731
39. Schlom J., Arlen P.M., and Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13 July (13) (2007) 3776-3782
40. Tsang K.Y., Palena C., Yokokawa J., Arlen P.M., Gulley J.L., Mazzara G.P., et al. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res 11 February (4) (2005) 1597-1607